Veru (NASDAQ:VERU) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Veru (NASDAQ:VERU – Free Report) from a hold rating to a sell rating in a report issued on Sunday,Wall Street Zen reports.

Several other research firms also recently weighed in on VERU. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Veru in a research report on Thursday, June 4th. Weiss Ratings downgraded Veru from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.50.

Get Veru alerts:

Check Out Our Latest Research Report on VERU

Veru Trading Up 1.2%

Shares of VERU stock opened at $2.56 on Friday. Veru has a 12-month low of $2.05 and a 12-month high of $7.33. The business’s 50 day moving average is $2.51 and its two-hundred day moving average is $2.52. The company has a market capitalization of $43.65 million, a P/E ratio of -3.71 and a beta of -1.17.

Veru (NASDAQ:VERU – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, research analysts predict that Veru will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VERU. FNY Investment Advisers LLC acquired a new position in shares of Veru during the 2nd quarter worth $328,000. Royal Bank of Canada increased its position in Veru by 69.3% during the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after buying an additional 5,008 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Veru in the first quarter worth $153,000. 47.16% of the stock is owned by hedge funds and other institutional investors.

About Veru

(Get Free Report)

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.

Further Reading

• Five stocks we like better than Veru
• CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
• CoreWeave Comes With Risks: Analysts Split on What Matters Most
• Bottlenecking the Future: TSMC Prices Out the Competition
• Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.